Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via...

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Clinical studies suggest minocycline, an anti-inflammatory agent, shows promise in treating depression.
• Mechanistic insights into minocycline's neuroprotective and anti-inflammatory effects are needed.
• Microglia activation is implicated in depression, correlating with decreased neurogenesis and increased depressive behaviors.

Purpose of the Study:

• To investigate the effect of minocycline on chronic mild stress (CMS)-induced depressive behaviors in mice.
• To elucidate the impact of minocycline on microglia activation in the hippocampus.
• To explore the direct effects of minocycline on microglia activation in vitro.

Main Methods:

• Behavioral assays were used to assess depressive-like behaviors.
• Immunohistochemistry was employed to examine microglia activation (CD68+) in different hippocampal regions of stressed mice.
• In vitro experiments, including western blotting and phagocytosis assays, were conducted on primary microglia activated by lipopolysaccharide (LPS).

Main Results:

• Minocycline administration ameliorated depressive behaviors in CMS-exposed mice.
• Chronic stress increased the number of activated microglia (CD68+) in the dorsal hippocampus (DG, CA1, CA2) and ventral hippocampus (DG).
• In vitro, minocycline reversed LPS-induced microglia activation, including ERK1/2 activation, iNOS expression, and enhanced phagocytic activity.

Conclusions:

• Minocycline effectively reverses depressive behaviors and neuroinflammatory changes associated with chronic stress.
• The findings suggest minocycline acts directly on microglia to reduce their phagocytic potential, mitigating neurotoxic M1 phenotypes.
• Minocycline may counteract chronic stress-induced reductions in neurogenesis by modulating microglia activation.